Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H21NO2 |
Molecular Weight | 247.3327 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=O)C1(CCN(C)CC1)C2=CC=CC(O)=C2
InChI
InChIKey=ALFGKMXHOUSVAD-UHFFFAOYSA-N
InChI=1S/C15H21NO2/c1-3-14(18)15(7-9-16(2)10-8-15)12-5-4-6-13(17)11-12/h4-6,11,17H,3,7-10H2,1-2H3
Ketobemidone (Cliradon, Ketogan, Ketodur, Cymidon) is a strong opioid analgesic, structurally related to pethidine, which has been in clinical use for more
than 50 years. In the Scandinavian countries ketobemidone is only available in combination with a spasmolytic
substance N,N-dimethyl-3,3-diphenyl-I-methylallylamine
(A29). Ketobemidone has been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In spite of a relatively low mu-receptor affinity ketobemidone has a higher analgesic potency than morphine by
systemic administration. It is probably due to its higher
lipophilicity and consequently more easy penetration into
the CNS. Ketobemidone is indicated for the treatment of all types of severe pain, such as postoperative, cancer, kidney stones and fractures.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Comparison of opioid agonists in maintaining responding and in suppressing morphine withdrawal in rhesus monkeys. | 1981 |
|
Determination of ketobemidone and its metabolites in plasma and urine using solid-phase extraction and liquid chromatography-mass spectrometry. | 2001 Aug |
|
Identification of glucuronide conjugates of ketobemidone and its phase I metabolites in human urine utilizing accurate mass and tandem time-of-flight mass spectrometry. | 2002 Apr |
|
Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. | 2002 May |
|
Wound infiltration with ropivacaine and fentanyl: effects on postoperative pain and PONV after breast surgery. | 2003 Mar |
|
Stability of drugs in stored postmortem femoral blood and vitreous humor. | 2004 Jul |
|
Ibuprofen vs. acetaminophen vs. ibuprofen and acetaminophen after arthroscopically assisted anterior cruciate ligament reconstruction. | 2004 Jun |
|
Comparison of the analgesic efficacy of ketobemidone and morphine for management of postoperative pain in children: a randomized, controlled study. | 2004 Nov |
|
Fracture risk associated with the use of morphine and opiates. | 2006 Jul |
|
[The use of analgesics in Denmark, 2000-2004]. | 2006 May 15 |
|
Laparoscopic occlusion compared with embolization of uterine vessels: a randomized controlled trial. | 2007 Jan |
|
Determination of 19 drugs of abuse and metabolites in whole blood by high-performance liquid chromatography-tandem mass spectrometry. | 2010 Apr |
|
In vivo investigation of brain and systemic ketobemidone metabolism. | 2010 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://drugs.tripsit.me/ketobemidone
Curator's Comment: The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or sulfate and circa 8 mg of ketobemidone by injection. https://www.drugbank.ca/drugs/DB06738
Oral
Light 5mg
Common 5-10mg
Strong 10-15mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8153059
Curator's Comment: Affinities of ketobemidone and morphine for Mu, Delta and Kappa opioid
receptors in bovine caudate nucleus were determined.
The affinity of ketobemidone to the mu-receptor is significantly lower than that of morphine considering Ki values of
5.5 and 2.4 nM respectively. At the delta-binding site the
two opioids have equal affinity (Ki values 143 versus 136
nM), whereas ketobemidone has much lower affinity than
morphine to the kappa-receptor (Ki 599 versus 130 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN02AG02
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
||
|
WHO-VATC |
QN02AB01
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
||
|
WHO-ATC |
N02AG02
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
||
|
WHO-ATC |
N02AB01
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
||
|
DEA NO. |
9628
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
117863
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
PRIMARY | |||
|
1274
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
C012394
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
PQS1L514CF
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
SUB08370MIG
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
DTXSID00196977
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
DB06738
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
KETOBEMIDONE
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
PRIMARY | |||
|
1526
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
100000083095
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
PRIMARY | |||
|
469-79-4
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
C80583
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
PRIMARY | |||
|
m6618
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
10101
Created by
admin on Fri Dec 15 16:04:51 UTC 2023 , Edited by admin on Fri Dec 15 16:04:51 UTC 2023
|
PRIMARY | |||
|
207-421-0
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL47072
Created by
admin on Fri Dec 15 16:04:50 UTC 2023 , Edited by admin on Fri Dec 15 16:04:50 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)